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ECP is largely used in Acute and Chronic GVHD patients.
Moreover, some multicenter studies are ongoing to evaluate future
ECP employment in GVHD prevention. Therefore, laboratory
and clinical parameters predictive of ECP response would be ex-
tremely useful. For istance, recent published data shown great
interest on VBTCR oligoclonal CD4 or CD8 subsets, and T reg
CD4CD25 CTLA 4/-, which could be used as predictive
factors for GVHD outcome.
We present data from seriate, cytoﬂuorimetry phenotype studies
performed on 200 blood samples from 4 aGVHD and 13 cGVHD
patients that underwent ECP in our Apheresis Unit.
15/17 had skin involvement oral mucose and/or ocular disease,
3/17 showed liver GVHD, 2/17 had lung function compromised.
Schedule for ECP therapy established 6 and 12 months of treat-
ment for Acute or Chronic GVHD, respectively.Clinical evalua-
tion was made every three months and according to known pro-
tocols.Skin and oral mucosa improvement was achieved in the 64%
of the patients, liver recovery was stabilized in the 30%, while no
response was reported in lung function.
Finally, after more than 6 months of treatment, 3/14 cGVHD
patients failed to respond and 3/14 maintained stable disease with-
out steroids administration.
A pathological increment of the VBTCR CD4 or CD8 oli-
goclones (being ﬁxed as 15% of the circulating lymphocytes) was
found in 10/17 patients. VB20, VB16, VB14 and VB3 were the
most recurrent oligoclones, but we could ﬁnd only weak correla-
tions with ECP response-rate, kind and extension of GVHD. At
the start of ECP, Treg CD4CD25CTLA4 (mean 0.4% of
the circulating CD4) were detected in all 2 cGVHD and in 1
aGVHD early responders to ECP. This subset was lacking in 3
ECP refractory patients in which, on the contrary, was detectable
the subset CD4CD25CTLA4- (mean 1.6% of the circulating
CD4) also detectable in the other 11 remaining patients. Inter-
estingly, in this last group of subjects Treg cells seemed to be
correlated to the ECP response rate. In particular, responders
showed inverse trends in the CTLA4 (increasing) or CTLA4-
(decreasing) subsets during ECP treatment.
In conclusion, Treg subpopulations seem to be useful as predic-
tive factors of GVHD outcome, in accordance with other studies
results. Nevertheless, further research is still necessary in order to
draw deﬁnitive conclusions.
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CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE
1 IS AN IMPORTANT SUPPRESSOR OF INTESTINAL AND SYSTEMIC
ACUTE GRAFT-VERSUS-HOST-DISEASE
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Carcinoembryonic antigen related cell adhesion molecule 1
(CEACAM-1) is a transmembrane glycoprotein found on leukco-
cytes, endothelium, and epithelium, and its activation can attenu-
tate colitis in murine models. Microarray analysis revealed that
CEACAM-1 expression is increased during gut graft-versus-host-
disease (GVHD). We studied the role of CEACAM-1 in a mouse
allogeneic bone marrow transplantation model (B63BALB/c]).
Using CEACAM-1-/- mice as recipients or T cell donors caused
sigiﬁcantly worse GVHD (p0.05) compared to wildtype (WT)
controls.
Histopathological analysis of GVHD target organs from
CEACAM-1-/- recipients of WT T cells revealed signiﬁcantly
increased GVHD of the large bowel (p0.05) and the thymus
(p0.05) as compared with WT controls.
Additionally, alloreactive splenic CD8 CEACAM-1-/- T cells
from recipients with GVHD had increased levels of 
47 integrin
(LPAM) as compared to WT controls. We also found increased
numbers of intraepithelial lymphocytes and mesenteric lymph
node cellularity in CEACAM-1-/- recipients of WT T cells.
Furthermore, adoptive transfer of CFSE-labeled CEACAM-1-/-
T cells into WT hosts, or of WT T cells into CEACAM-1-/- hosts
revealed more profound activation of T cells in the CEACAM-1
deﬁcient setting as demonstrated by increased early CD25 expres-
sion and CD62L downregulation on fast-cycling alloreactive T
cells in the spleen and liver.
We found no signiﬁcant differences in serum levels of TNF-
 or
interferon-, T cell proliferation kinetics upon adoptive transfer,
percentages of alloactivated CD4 and CD8 cells, or percentages of
CD4FoxP3 regulatory T cells in WT recipients of CEACAM-
1-/- T cells, CEACAM-1-/- recipients of WT T cells, and WT
recipients of WT T cells.
We conclude that CEACAM-1 deﬁciency on donor T cells or in
recipients results in increased gut and systemic GVHD due to
increased T cell activation and expression of the gut homing
integrin 
47. This suggests that the use of CEACAM-1 agonists
could be a novel theraputic strategy for ameliorating acute intes-
tinal and systemic graft-versus-host-disease. Studies with an ago-
nistic CEACAM-1 antibody are currently under way.
331
GLOBAL ASSESSMENT OF B CELL ALLOIMMUNITY USING MICROAR-
RAYS OF 5000 HUMAN PROTEINS
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Allogeneic Hematopoietic Cell Transplantation (HCT) can cure
hematologic malignancies through beneﬁcial graft-v-leukemia (GVL)
allo-immune responses, but is limited by graft-versus-host disease
(GVHD). Recent studies demonstrate allogeneic antibodies (Ab) de-
velop against minor histocompatibility antigens (mHA) encoded on
the Y-chromosome (H-Y antigens) develop after sex-mismatch HCT
in association with chronic GVHD and persistent disease remission.
We hypothesize that novel mHA can be serologically identiﬁed as
targets of allo-Ab responses that develop post-transplant but are ab-
sent pre-transplant. ProtoArray™ (Invitrogen) displays 5,000 full-
length human proteins with N-terminal GST epitopes expressed in
baculovirus and afﬁnity puriﬁed under native conditions maintaining
their cellular enzymatic activities/native conformations. Technical
replicates of 8 plasma measured at 1:50, 1:150, 1:500 provided corre-
lation coefﬁents, R20.94-0.97 conﬁrming technical feasibility. In
order to identify targets of allo-Ab, pretransplant ﬂuorescent signal
intensities were subtracted from their one-year plasma results for all
5000 antigens. While Ab responses were unchanged for 4600 (92%)
antigens, new allo-Ab responses targeted 60-75 antigens with ﬂuores-
cent differences ranging 0.5 to 3 logs. In comparison with their
respective donor results, 30-40% appear to result from adoptive do-
nor transfer while the remaining develop de novo . Over 90% of
allo-Ab targets have known non-synonymous SNP which when dis-
parate in donor and recipient may elicit alloimmunity and this geno-
typing is ongoing. No single protein was recognized by “new” Ab
responses in all patients, however polymorphic proteins Growth Ar-
rest Speciﬁc-7 (GAS7), laminin A/C, and ribosomal protein S19
(RPS19) were recognized by two of the four patients after HCT.
Results from plasma samples collected 3, 6, 9 and 12 months after
HCT demonstrate the progression of alloimmune immune responses.
Though these novel mHA require validation by large clinically char-
acterized patient samples, protein microarrays are innovative, power-
ful tools for high-throughput global assessment of B -cell alloimmu-
nity after HCT providing sufﬁcient reproducibility for candidate
mHA discovery.
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EFFECTIVE GRAFT-VERSUS-LEUKEMIA RESPONSES ARE ASSOCIATED
WITH THE PRESENCE OF NUCLEIC ACID-IMMUNOGLOBULIN COM-
PLEXES THAT STIMULATE TOLL-LIKE RECEPTORS (TLR) 8 AND 9
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In patients with chronic myeloid leukemia (CML) who demon-
strated effective graft-versus-leukemia (GvL) responses after DLI
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